|
|
|
| Clinical Efficacy and Safety Analysis of Emaglutide in Overweight and Obese Patients with Type 2 Diabetes Mellitus |
| LI Yanni, LIU Hongli, WANG Yeju, et al |
| Hanzhong Central Hospital,Shannxi Hanzhong 723000, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy and safety of smegliptide in overweight or obese (T2DM) patients with type 2 diabetes mellitus. Methods: Eighty overweight or obese patients with T2DM admitted in Hanzhong Central Hospital, Shaanxi Province from January 2022 to June 2022 were enrolled for the study and divided into observation group (n = 40) and control group (n = 40) through simple random grouping method. On the basis of diet control and aerobic exercise, patients in the control group and observation group were metformin, metformin + smeglutide respectively. The blood glucose, body weight, blood lipid, blood pressure and adverse reactions were compared between the two groups before intervention and 12 weeks after intervention. Results: Compared with the level before the intervention within group, the fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPPG), glycosylated hemoglobin (HbAlc), homeostasis model assessment of insulin resistance index (HOMA-IR), body mass index (BMI), total triglyceride (TG), total cholesterol (TC), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the two groups significantly decreased after the intervention, and the homeostasis model assessment of islet β cell function index (HOMA-β) significantly increased (P<0.05). Compared with the control group, the difference of FPG, 2hPPG, HbAlc, HOMA-IR, HOMA-β, BMI, SBP, DBP, TG, TC before and after intervention in observation group significantly increased (P<0.05). There were no significant differences in the incidences of adverse reactions between two groups (P>0.05). Conclusion: Smegliptide could not only significantly reduce the blood glucose level of T2DM patients with overweight or obese, but also strengthen the control of body weight, blood lipid and blood pressure, improve insulin resistance. It is safe, reliable and worthy of clinical application.
|
|
|
|
|
|
[1] 陈娇月,山秀杰,刘敏,等.骨化三醇联合二甲双胍对腹型肥胖2型糖尿病早期肾病的影响[J].河北医学,2020,26(4):602-605.
[2] 刘天洋.GLP-1类似物-司美格鲁肽研究进展[J].中国处方药,2022,20(3):182-183.
[3] 邢国庆,于苏国.司美格鲁肽治疗肥胖的研究进展[J].国际医药卫生导报,2022,28(7):898-901.
[4] 赵楠,许杰,李晓晨,等.腹部脂肪分布对2型糖尿病患者人体成分及胰岛功能的影响[J].国际内分泌代谢杂志,2019,39(6):361-367.
[5] 任品宽.奥利司他胶囊联合二甲双胍在超重或肥胖2型糖尿病患者治疗中的疗效及安全性[J].基层医学论坛,2020,24(31):4462-4464.
[6] 夏晓英,李枢,孙诗博,等.卡格列净联合二甲双胍对初诊超重或肥胖2型糖尿病患者的疗效及体脂、代谢状态的影响[J].中国医药指南,2020,18(24):35-37.
[7] 赵帆,林昕,何訸,等.GLP-1类似物治疗2型糖尿病的Meta分析[J].重庆医学,2019,48(18):3159-3166.
[8] Lingvay I,Catarig AM,Frias JP, et al.Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8):a double-blind,phase 3b,randomised controlled trial[J].Lancet Diabetes Endocrinol,2019,7(11):834-844.
[9] Zinman B,Bhosekar V,Busch R,et al.Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9):a randomised,placebo-controlled trial[J].Lancet Diabetes Endocrinol,2019,7(5):356-367.
[10] Gerstein HC,Colhoun HM,Dagenais GR,et al.Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND):a double-blind,randomised placebo-controlled trial[J].Lancet,2019,394(10193):121-130. |
| [1] |
. [J]. HeBei Med, 2023, 29(4): 696-698. |
|
|
|
|
2023, Vol. 29 
